Natalia L Laufer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5119911/publications.pdf

Version: 2024-02-01

46	808	516561 16	552653 26
papers	citations	h-index	g-index

50	50	50	1459
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation. Annals of Internal Medicine, 2022, 175, 95-100.	2.0	36
2	Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time. MBio, 2022, 13, e0344221.	1.8	19
3	SARS-CoV-2 humoral and cellular immune responses in COVID-19 convalescent individuals with HIV. Journal of Infection, 2022, 85, 334-363.	1.7	4
4	Immune variations throughout the course of tuberculosis treatment and its relationship with adrenal hormone changes in HIV-1 patients co-infected with Mycobacterium tuberculosis. Tuberculosis, 2021, 127, 102045.	0.8	0
5	Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose. Cell Reports Medicine, 2021, 2, 100359.	3.3	62
6	Pre-cART Immune Parameters in People Living With HIV Might Help Predict CD8+ T-Cell Characteristics, Inflammation Levels, and Reservoir Composition After Effective cART. Pathogens and Immunity, 2021, 6, 60-89.	1.4	2
7	Dynamics of SARS-CoV-2-specific antibodies among COVID19 biobank donors in Argentina. Heliyon, 2021, 7, e08140.	1.4	7
8	7-oxo-DHEA enhances impaired M. tuberculosis-specific T cell responses during HIV-TB coinfection. Journal of Biomedical Science, 2020, 27, 20.	2.6	4
9	Hepatitis C Virus (HCV) Clearance After Treatment With Direct-Acting Antivirals in Human Immunodeficiency Virus (HIV)-HCV Coinfection Modulates Systemic Immune Activation and HIV Transcription on Antiretroviral Therapy. Open Forum Infectious Diseases, 2020, 7, ofaa115.	0.4	11
10	Liver cirrhosis in <scp>HIV</scp>/<scp>HCV</scp>â€coinfected individuals is related to <scp>NK</scp> cell dysfunction and exhaustion, but not to an impaired <scp>NK</scp> cell modulation by <scp>CD</scp>4⁺ Tâ€cells. Journal of the International AIDS Society, 2019, 22, e25375.	1.2	11
11	Impact of HIV-ART on the restoration of Th17 and Treg cells in blood and female genital mucosa. Scientific Reports, 2019, 9, 1978.	1.6	22
12	PD-1 Expression in HIV-Specific CD8+ T cells Before Antiretroviral Therapy Is Associated With HIV Persistence. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 1-6.	0.9	21
13	Phenotype, Polyfunctionality, and Antiviral Activity of in vitro Stimulated CD8+ T-Cells From HIV+ Subjects Who Initiated cART at Different Time-Points After Acute Infection. Frontiers in Immunology, 2018, 9, 2443.	2.2	12
14	Biomarkers of Progression after HIV Acute/Early Infection: Nothing Compares to CD4+ T-cell Count?. Viruses, 2018, 10, 34.	1.5	10
15	Evaluation of Different Parameters of Humoral and Cellular Immune Responses in HIV Serodiscordant Heterosexual Couples: Humoral Response Potentially Implicated in Modulating Transmission Rates. EBioMedicine, 2017, 26, 25-37.	2.7	15
16	Extrahepatic manifestations of HCV: the role of direct acting antivirals. Expert Review of Anti-Infective Therapy, 2017, 15, 737-746.	2.0	21
17	Expansion of CD25-Negative Forkhead Box P3-Positive T Cells during HIV and Mycobacterium tuberculosis Infection. Frontiers in Immunology, 2017, 8, 528.	2.2	30
18	Phylogenetic Diversity in Core Region of Hepatitis C Virus Genotype 1a as a Factor Associated with Fibrosis Severity in HIV-1-Coinfected Patients. BioMed Research International, 2017, 2017, 1-12.	0.9	3

#	Article	IF	Citations
19	CD4⁺ T cells and natural killer cells: Biomarkers for hepatic fibrosis in human immunodeficiency virus/hepatitis C virus-coinfected patients. World Journal of Hepatology, 2017, 9, 1073.	0.8	3
20	Modification of the HIV-specific CD8+ T-cell response in an HIV elite controller after chikungunya virus infection. Aids, 2016, 30, 1905-1911.	1.0	6
21	Evolution of hepatitis C virus in HIV coinfected patients under antiretroviral therapy. Infection, Genetics and Evolution, 2016, 43, 186-196.	1.0	1
22	Env-Specific IgA from Viremic HIV-Infected Subjects Compromises Antibody-Dependent Cellular Cytotoxicity. Journal of Virology, 2016, 90, 670-681.	1.5	39
23	Th17 and Th17/Treg ratio at early HIV infection associate with protective HIV-specific CD8+ T-cell responses and disease progression. Scientific Reports, 2015, 5, 11511.	1.6	47
24	HIVâ€“TB coinfection impairs CD8⁺ Tâ€cell differentiation and function while dehydroepiandrosterone improves cytotoxic antitubercular immune responses. European Journal of Immunology, 2015, 45, 2529-2541.	1.6	11
25	Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV/HIV co-infected patients. International Journal of Antimicrobial Agents, 2015, 46, 219-224.	1.1	7
26	HIV-1 Tropism Dynamics and Phylogenetic Analysis from Longitudinal Ultra-Deep Sequencing Data of CCR5- and CXCR4-Using Variants. PLoS ONE, 2014, 9, e102857.	1.1	15
27	Inter and intra-host variability of hepatitis C virus genotype 1a hypervariable envelope coding domains followed for a 4â€“11 year of human immunodeficiency virus coinfection and highly active antiretroviral therapy. Virology, 2014, 471-473, 19-28.	1.1	6
28	Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV. Expert Review of Anti-Infective Therapy, 2014, 12, 157-164.	2.0	2
29	HIV-1 Env-specific IgA/IgG Ratio Is Related to Antibody Dependent Cellular Cytotoxicity (ADCC) Responses Observed during Acute/Early HIV Infection. AIDS Research and Human Retroviruses, 2014, 30, A89-A89.	0.5	1
30	MicroRNAs differentially present in the plasma of HIV elite controllers reduce HIV infection in vitro. Scientific Reports, 2014, 4, 5915.	1.6	82
31	Early Skewed Distribution of Total and HIV-Specific CD8+ T-Cell Memory Phenotypes during Primary HIV Infection Is Related to Reduced Antiviral Activity and Faster Disease Progression. PLoS ONE, 2014, 9, e104235.	1.1	28
32	Host Genetic Factors Associated with Symptomatic Primary HIV Infection and Disease Progression among Argentinean Seroconverters. PLoS ONE, 2014, 9, e113146.	1.1	15
33	Early Gag Immunodominance of the HIV-Specific T-Cell Response during Acute/Early Infection Is Associated with Higher CD8 ⁺ T-Cell Antiviral Activity and Correlates with Preservation of the CD4 ⁺ T-Cell Compartment. Journal of Virology, 2013, 87, 7445-7462.	1.5	53
34	ICOS, SLAM and PD-1 expression and regulation on T lymphocytes reflect the immune dysregulation in patients with HIV-related illness with pulmonary tuberculosis. Journal of the International AIDS Society, 2012, 15, 17428.	1.2	12
35	Longitudinal analysis of the 5â€²UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients. Antiviral Research, 2012, 95, 72-81.	1.9	8
36	A clustering phenomenon among HCVâ€1a strains among patients coinfected with HIV from Buenos Aires, Argentina. Journal of Medical Virology, 2012, 84, 570-581.	2.5	6

#	Article	IF	Citations
37	Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinean seroconverters. Journal of the International AIDS Society, 2011, 14, 40-40.	1.2	55
38	The Coughing Patient: TB or Not TB; That Is The Question. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 562-563.	0.9	2
39	The Hepatitis C Virus 5â€²UTR Genomic Region Remains Highly Conserved Under HAART: A 4- to 8-Year Longitudinal Study from HCV/HIV Co-Infected Patients. AIDS Research and Human Retroviruses, 2010, 26, 527-532.	0.5	5
40	Telomerase activity in peripheral blood mononuclear cells from HIV and HIVâ€“HCV coinfected patients. Virus Research, 2010, 147, 284-287.	1.1	7
41	Hepatitis B Virus, Hepatitis C Virus and HIV Coinfection Among People Living With HIV/AIDS in Buenos Aires, Argentina. Sexually Transmitted Diseases, 2010, 37, 342-343.	0.8	17
42	Hepatitis B precore/core promoter mutations in isolates from HBV-monoinfected and HBVâ€“HIV coinfected patients: A 3-yr prospective study. Journal of Clinical Virology, 2009, 46, 354-359.	1.6	20
43	Magnitude, Breadth, and Functional Profile of T-Cell Responses during Human Immunodeficiency Virus Primary Infection with B and BF Viral Variants. Journal of Virology, 2008, 82, 2853-2866.	1.5	34
44	Uncommon Hepatitis B Virus and/or Hepatitis C Virus Occult Infection in HIV-Positive Patients With Abnormal Level of Hepatic Enzyme. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 233-234.	0.9	1
45	Low Rate of Emergence of Nevirapine and Lamivudine Resistance after Post-Partum Interruption of a Triple-Drug Regimen. Antiviral Therapy, 2008, 13, 135-140.	0.6	12
46	HCV genotype distribution among HIV co-infected individuals in Argentina: relationship with host and viral factors. Acta Gastroenterologica Latinoamericana, 2007, 37, 76-83.	0.0	16